President’s Message

Myrtle Davis, DVM, Ph.D.

Greetings! Since the SOT Annual Meeting is only a few weeks away, I will begin by encouraging all who are planning to attend to the meeting in San Diego (March 5-9) to join your fellow CVSS members at the CVSS Luncheon and Annual Meeting. The CVSS luncheon will be held on Monday March 6, 2006 from 12:30-1:30 in the Convention center in Room #4. For the first time, SOT provided select specialty sections with the opportunity to take advantage of a luncheon reception. One big advantage to the lunch time meeting as compared to the evening reception is the cost savings of nearly $1,000 to the CVSS! It will also give many of our members with membership to multiple SS the opportunity to attend evening receptions held by other sections. We know that CVSS Members always give preference to the CVSS reception so we thought this would demonstrate our consideration to the other SS! (smile)

The CVSS is the first specialty section chartered to bring together SOT members who share and interest in comparative, veterinary and in vivo toxicology. Thus far, approximately 80% of our 2005 CVSS members have renewed their membership for 2006! If you have not already done so, please renew your membership today. Your membership allows CVSS to continue a tradition of providing a forum for scientists and students with these unique interests.

Annual Meeting Activities

Specialty Section Presidents' and Vice Presidents' Meeting
Room 14B - Monday, March 6, 2006, 4:30 p.m. - 6:00 p.m.

The CVSS Officer’s Meeting
Room 4, Monday March 6, 2006, 6:15 am, room 4
Modified student award format was a success

One key achievement for 2005 was the modification of our student award. For the past several years, CVSS has sponsored two annual student awards for best manuscript. CVSS experienced a notable decline in the numbers of submissions for our student award in some years, between 2002-2005 received only two submissions. During the Officers meeting in 2004, it was observed that in contrast to the majority of other specialty sections, CVSS was one of the few that required a full submitted manuscript for consideration. Although the manuscript format was an opportunity for advanced students to be recognized, the numbers of active graduate students who were able to apply for this award were limited. It was decided that we should modify our award to a poster submission. This year’s change in criteria was associated with a tremendous increase in the numbers of submissions for the student award. We received over twenty submissions this year and all supported the mission of the CVSS to support research in the area of in vivo toxicology. The real win here is the expansion of Student Awareness of CVSS. Our Student award is one of the major ways the CVSS is contributing to the effort to increase student participation in SOT and the CVSS. All CVSS members are encouraged to meet the finalists at their posters during annual meeting. The times and dates for these poster presentations are included below. Two winners will be announced and awards ($500, $300 and plaques to both) presented at the CVSS luncheon. Thanks to Dan Ness (CVSS VP. Elect) and the awards committee for making this year one of the highest ever for high quality student award submissions.

### 2006 Student Award Finalists

<table>
<thead>
<tr>
<th>Finalist</th>
<th>Poster number and title</th>
<th>Sponsor</th>
<th>Poster Session date and time (All in Convention Center Exhibit Hall)</th>
</tr>
</thead>
</table>
| Neal Burton  
Johns Hopkins  
Bloomberg School of Public Health | 502. *In vivo* attenuation of the parkinsonian phenotype by induction of the Nrf2-Keap1 pathway | Tomas Guilarte | Monday, March 06, 2006 1:30 PM-4:30 PM, Oxidative Injury Mechanisms |
| Jaya Chilakapati  
U. of Louisiana at Monroe | 688. Role of thioacetamide-sulfoxide metabolism in saturation kinetics of thioacetamide | Harihara Mehendale | Monday, March 06, 2006 1:30 PM- 4:30 PM, Metabolism Toxicity and Polymorphisms |
| Steven Cooper  
FDA-NCTR | 459. Dietary effects on cell proliferation and apoptosis in para-nonylphenol (NP) induced polycystic kidney disease (PKD) in male Sprague-Dawley rats | K. Barry Delclos | Monday, March 06, 2006 1:30 PM-4:30 PM, Kidney |
| Lijoy Mathew  
Oregon State University | 222. AHR signaling and gene expression changes during regenerative growth | Robert Tanguay | Monday, March 06, 2006 9:30 AM-12:00 PM, Ah receptor I |
## 2006 Student Award Finalists Continued

<table>
<thead>
<tr>
<th>Finalist</th>
<th>Poster number and title</th>
<th>Sponsor</th>
<th>Poster Session date and time (All in Convention Center Exhibit Hall)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kerstin Stemmer</td>
<td>447. Expression profiles induced by renal carcinogens in Eker rats compared to wildtype rats</td>
<td>Daniel Dietrich</td>
<td>Monday, March 06, 2006 1:30 PM-4:30 PM, Kidney</td>
</tr>
<tr>
<td>U. of Konstanz Germany</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flavia Pereira</td>
<td>423. Initiation and progression of atherosclerosis in ApE−/−/LDLR−/− mice exposed to arsenic in drinking water</td>
<td>Howard Beall</td>
<td>Monday, March 06, 2006 1:30 PM-4:30 PM, Arsenic Toxicology</td>
</tr>
<tr>
<td>U. of Montana</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sharmilee Sawant</td>
<td>1008. Type 2 diabetic mice are protected from acetaminophen hepatotoxicity</td>
<td>Harihara Mehendale</td>
<td>Tuesday, March 07,2006 9:00 AM-12:00 PM, Acetaminophen</td>
</tr>
<tr>
<td>Johnson and Johnson (post doctoral)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jason Walraven</td>
<td>968. A novel polymorphic rat N-acetyltransferase allele (Nat3*2) with reduced catalytic activity <em>in vitro</em></td>
<td>David Hein</td>
<td>Tuesday, March 07,2006 9:00 AM-12:00 PM, Carcinogenesis Mechanisms</td>
</tr>
<tr>
<td>U. of Louisville</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifang Xie</td>
<td>1660. Discovery of Cystatin C as a biomarker of cardiac cell type specific oxidative injury with shotgun proteomics</td>
<td>Qin Chen</td>
<td>Wednesday, March 08, 2006 9:00 AM-12:00 PM, Disease and Toxicity Biomarkers</td>
</tr>
<tr>
<td>U. of Arizona</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CVSS Elections 2006.

One responsibility of the serving Past President of the CVSS is to create the Ballot for the year’s upcoming elections. This year we need to elect a Vice President Elect and a Councilor. Bill Valentine has received several nominees for these positions and is currently working on the 2006 ballot. Look forward to seeing the ballot which will be sent to you by email within the next couple of weeks. Thanks to Bill for all of his hard work.

### Specialty Section Leaders met in Chicago to discuss the future

Officers from all but one specialty section (SS) met last August with Ken Wallace, SOT President, and Michael Holsapple, the SOT Council liaison for the SSs. Dan Ness, VP elect, represented CVSS.
Ken Wallace was complimentary on the SSs past successes but challenged the group to consider what it could do throughout the year to support the Society’s Long Range Plan and SOT Vision statement. Some recommendations were:

- Develop Current Concepts in Toxicology (CCT) Meetings
- Help develop position papers on special issues
- Help populate scientific review panels, and
- Help develop congressional briefings.

Breakout sessions focused on 1) student involvement and 2) how to encourage members to join SS’s and how to better market the value of SSs. Great interest was shown in developing a monthly, web-based seminar series wherein each SS would be responsible for one month. **If you have any ideas about a presentation that would be instructive and that captures the mission of CVSS please bring them to the luncheon on March 6 or contact a CVSS officer.**

If you would like more detailed information of this summer session please contact Rita Rose at SOT Headquarters.

---

**CVSS is proud to sponsor three exciting Continuing Education Courses at the upcoming Society of Toxicology Annual Meeting in San Diego**

All continuing Education Courses are offered on Sunday March 5, 2005 (AM 8:15-12:00 Noon) or PM (1:15-5:00).

**AM5- Comparative Endocrine Toxicology** -Chair: Stephen B. Hooser

Description: Hormones secreted by cells of the endocrine system have diverse effects throughout the body. Exposure to xenobiotic compounds can result in profound changes to the endocrine organs and/or their target cells. Significant species differences exist in the structure and function of endocrine and reproductive organs making interpretation of test results and extrapolation from animal models to humans more challenging. In addition to the numerous anatomical and physiological differences, there are also species variations in metabolism and response to toxicants. It is the goal of these presentations to give an overview of the structure, function, regulation, and toxic responses of selected endocrine and reproductive organs. In addition, the speakers will discuss the hormonal assays and other mechanistic approaches necessary to make species comparisons, and to extrapolate the findings from animals to humans. Each presentation will briefly describe important species differences with regard to anatomy, endocrine physiology, and response to different classes of xenobiotic chemicals by selected endocrine and reproductive organs such as the thyroid (follicular cells), ovary, and testis (Leydig cells). One presentation will focus on the principles and pitfalls of hormonal measurements in laboratory animals considering advantages/disadvantages of different methods, species specificity of certain assays, most appropriate sampling times, and other useful items to consider in future protocol development. Following completion of this workshop, attendees should have a more complete understanding of the comparative endocrinology and toxicology of selected endocrine and reproductive organs in laboratory animals.

**AM2/PM08- Targeted Therapeutic Approach to Anti-Cancer Drug Development**
Chairs: Vijayapal Reddy and Myrtle Davis
**Description:** Over the past decade, a range of targeted anti-cancer drugs have been developed that are designed to interfere with one or more of the many molecular mechanisms that drive tumor growth. The molecularly-targeted approach to the development of these new anti-cancer drugs has created a false impression that these newer drugs, unlike earlier cytotoxic anti-cancer drugs, will be non-toxic. Cytotoxic drugs are typically administered in short courses of maximal doses (MTD). This is not necessarily appropriate for targeted therapies, which can require long-term therapy and for which it is often difficult to determine the biologically most effective dosage (BED). This course will focus on different aspects of regulatory, preclinical, and clinical targeted anti-cancer drug development. The first speaker will focus on tumor cell biology and the respective cell signaling pathways that hold promise for targeted anti-cancer therapy. The second speaker will present differences in preclinical development philosophy between cytotoxic and targeted anti-cancer drugs. The third speaker will discuss specific examples of preclinical development of targeted biotherapeutics. The fourth speaker will discuss biomarkers as endpoints of clinical efficacy and safety assessment. The final speaker will focus on regulatory considerations of preclinical development of targeted therapies, highlighting differences between cytotoxic and targeted therapies. This advanced course in drug development is targeted to government, biotechnology and pharmaceutical toxicologists as well as general toxicologists with an interest in cancer chemotherapy.

**PM12-Neuropathology for the Toxicologist -Chair: David Dorman**
**Description:** This course is designed to provide a basic overview of rodent neuropathology. The course will start off with a review of the normal anatomy and histology of the adult nervous system. This overview will also discuss the ways in which neuropathology and functional assays of motor activity and other behaviors relate to one another. The second lecture relates to tissue handling techniques and basic approaches in neuropathology. This topic is critically important since the ability to detect chemical-induced neuropathology requires proper tissue fixation and processing. Although the second lecture will largely focus on rodent tissues, the approaches and methods to be discussed can be easily adapted to other species. The course will then transition into two presentations focused on common lesions induced by model neurotoxicants. One presentation will focus on central nervous system effects while the latter lecture will address peripheral neuropathies. Our final presentation will discuss morphometric approaches in neuropathology including a discussion of the use of magnetic resonance imaging methods in neurotoxicologic pathology. Participants in this course will gain a greatly improved appreciation of basic neuropathology and applications to toxicology.

**Soliciting Ideas and proposals for CE courses, Symposia or workshops for 46th SOT Annual Meeting in 2007**

Ideas for CE courses, Symposia or workshops for 2007 are needed from our members. Proposals must be submitted by April 30, 2006. If you need help in developing an idea, please contact the CVSS President or Vice President. The following article from the program committee will provide clarification on the process for selecting
Symposia, Workshops, Roundtables and Historical Highlight sessions for future meetings.

**Development and Selection of Symposia, Roundtables, Workshops and Historical Highlights (SWR and HH) proposals for the Society of Toxicology Annual Meeting.**

From the Program Committee

Proposals received by the Program Committee vary considerably in terms of the level of detail. Since we receive more proposals than can be accepted, we tend to give preference to those proposals that are most complete and therefore provide the best understanding of the proposed session. The following comments outline an "ideal" proposal submission.

Each proposal must contain the names and contact information of SOT members who will serve as session chair and co-chair. A complete abstract describing the session, including purpose, description of the information to be presented and the significance of this information must be included. The abstract should include an indication of why this proposed session is timely and why it would be of interest to the meeting attendees. In addition, there should be a separate brief paragraph for each individual presentation describing what each speaker will present. This should not be a recapitulation of the material in the session abstract, but should include more detailed information specific to the speaker. Potential speakers should be contacted prior to the submission of the proposal and their agreement to participate secured. Of course, the potential speaker should be informed that this is a tentative invitation contingent on acceptance of the session and contingent upon the final program having an appropriate balance of speakers.

**Proposal Evaluation Process by Program Committee**

The most important criterion for acceptance of proposals for SWRs and HH sessions is high-quality scientific reporting of new information or approaches, or new synthesis of information that enhances the field of toxicology. No member of the committee acts as an advocate for any particular proposal or specialty section. All proposals are reviewed and judged on the basis of the content as presented in the proposal.

During the May Program Committee meeting, every member of the committee reads every proposal and judges the quality and suitability of the material for the proposed session-type. Each proposal is then discussed by the full committee and a consensus is reached regarding its acceptability which is determined according to the following criteria:

- Quality of the topic to be presented
- Timeliness (a combination of current interest and recency of previous inclusion in the program)
- Appeal to the society membership
- Degree of development and detail
- Proposals lacking information sufficient to determine acceptability based on these criteria will be judged unacceptable.

All proposals meeting acceptability criteria are then tentatively accepted and returned to the proposers who are asked for development of the final proposal of the session which must include complete abstracts and final titles for each presentation. The committee may decide that a proposed
session is acceptable in a session-type different from the one proposed (e.g., a proposal may be judged more appropriate for a workshop than a symposium). In this case, the proposer has the option of either accepting the recommended session-type or withdrawing the proposal. Final proposals are evaluated in the September Program Committee meeting. Every final proposal is reviewed by every committee member and is again discussed by the full committee, and is accepted or rejected on the basis of evaluation criteria (see above). In most instances proposals that were tentatively accepted are fully accepted in September. However, if there are significant changes in the content of the proposal or it has not been adequately developed, the committee may reject a proposal at this stage.

To provide additional opportunity for clarification of any point prior to the development of the first submission, proposers are encouraged to contact any member of the Program Committee for assistance. While Committee members are happy to discuss the structure and content of proposals at an early stage of development, they can not act as an advocate for specific proposals and they should not be asked to do so. All decisions of the Committee are made by consensus after open discussion among members. Attachment 1 lists the names and contact information of Program Committee Members and the year of service for your immediate reference.

**Specialty Section Ranking and Comment on Proposals**

The Specialty Section evaluation includes both a ranking of the proposals and comments on the individual proposal. It is important that the ranking be done consistently across specialty sections. Therefore, the Program Committee requests that each Specialty Section rank the sessions for which they are offering the primary endorsement using a forced ranking approach. Each session within a session category (Symposium, Workshop Roundtable and Historical Highlights) should be ranked in a separate pool by session category i.e. Symposium 1 through x, Workshop 1 through x etc. There should be no multiple rankings within a session category. Multiple identical ranking are not helpful.

Comments from the specialty section are as important as the ranking. This past year, few comments were provided and the comments received tended to be limited in scope. Therefore, the Program Committee requests that each Specialty Section consider the following points in preparing comments particularly for sessions where the specialty section is the primary endorser.

- Timeliness of the topic
- Time since a similar topic was last presented at SOT
- Identification of target audience i.e. is this topic of broad interest or specialty interest.
- Quality of speakers both in terms of message as well as speaking skills
- Coherence of session. Is there a progressive development of a message?

Comments from Specialty Sections other than the primary endorsing section are always welcome. Please feel free to contact Jim Popp directly if you wish to follow-up on any of these points prior to interactions at the annual meeting.

Jim Popp Chairperson, SOT Program Committee  
Popp@Stratoxon.com  
717-735-3646
Upcoming Conferences and Events

Upcoming SOT Annual Meetings

45th Annual Meeting
March 5–9, 2006
San Diego Convention Center
San Diego, California

46th Annual Meeting
March 25–29, 2007
Charlotte Convention Center
Charlotte, North Carolina

For more information, see http://caat.jhsph.edu/dnt

The International Conference on Emerging Infectious Diseases 2006, March 19–22, 2006, at the Marriott Marquis in Atlanta, Georgia. For more information, visit http://www.iceid.org


2006 INTERNATIONAL CONFERENCE FRONTIERS OF PHARMACOLOGY AND TOXICOLOGY: Addressing Translational Research in Efficacy and Safety of New Medicines
AUGUST 28 - 31, 2006, THE RENAISSANCE CHICAGO HOTEL, CHICAGO, ILLINOIS
In Collaboration with UIC Cancer Center and leading scientists of the NCI, NIAID and FDA
For more information see http://www.uic.edu/labs/tox/frontiers
CVSS Officers 2005

Myrtle Davis, DVM, PhD, President

Wilson Kiiiza Rumbeiha, DVM, PhD, DABT, DABVT, Vice President

Daniel Ness, DVM, PhD, Vice President-elect

Randy Jones, DVM, PhD, DABT, DABVT, Secretary/Treasurer

William Valentine, DVM, PhD, DABT, DABVT, Past President

Jay Albretsen, DVM, PhD, Councilor

Laurene Fomby, DVM, PhD, DABVT, Councilor

Sachin Devi, Student Representative